🚀 VC round data is live in beta, check it out!
Crescent Capital BDC Valuation Multiples
Discover revenue and EBITDA valuation multiples for Crescent Capital BDC and similar public comparables like abrdn Life Sciences, Testa Residencial, Qualitas, Djerriwarrh Investments and more.
Crescent Capital BDC Overview
About Crescent Capital BDC
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
Founded
2015
HQ
Employees
230
Website
Sectors
Financials (LTM)
EV
$1B
Crescent Capital BDC Financials
Crescent Capital BDC reported last 12-month revenue of $164M.
In the same LTM period, Crescent Capital BDC generated $41M in net income.
Revenue (LTM)
Crescent Capital BDC P&L
In the most recent fiscal year, Crescent Capital BDC reported revenue of $167M and net income of $35M.
Crescent Capital BDC expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $164M | XXX | $167M | XXX | XXX | XXX |
| EBIT Margin | 40% | XXX | 40% | XXX | XXX | XXX |
| Net Profit | $41M | XXX | $35M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | — | — | $869M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Crescent Capital BDC Stock Performance
Crescent Capital BDC has current market cap of $496M, and enterprise value of $1B.
Market Cap Evolution
Crescent Capital BDC's stock price is $13.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $496M | 0.0% | XXX | XXX | XXX | $0.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCrescent Capital BDC Valuation Multiples
Crescent Capital BDC trades at 8.3x EV/Revenue multiple.
EV / Revenue (LTM)
Crescent Capital BDC Financial Valuation Multiples
As of April 10, 2026, Crescent Capital BDC has market cap of $496M and EV of $1B.
Equity research analysts estimate Crescent Capital BDC's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Crescent Capital BDC has a P/E ratio of 12.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $496M | XXX | $496M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 8.3x | XXX | 8.2x | XXX | XXX | XXX |
| EV/EBIT | 21.0x | XXX | 20.5x | XXX | XXX | XXX |
| P/E | 12.1x | XXX | 14.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 18.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Crescent Capital BDC Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Crescent Capital BDC Margins & Growth Rates
Crescent Capital BDC's revenue in the last 12 month declined by (6%).
Crescent Capital BDC's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.4M for the same period.
Crescent Capital BDC Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (6%) | XXX | (7%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | 53% | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Crescent Capital BDC Public Comps
See public comps and valuation multiples for other Asset Management comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| abrdn Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Testa Residencial | XXX | XXX | XXX | XXX | XXX | XXX |
| Qualitas | XXX | XXX | XXX | XXX | XXX | XXX |
| Djerriwarrh Investments | XXX | XXX | XXX | XXX | XXX | XXX |
| eQ | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Crescent Capital BDC M&A Activity
Crescent Capital BDC acquired XXX companies to date.
Last acquisition by Crescent Capital BDC was on XXXXXXXX, XXXXX. Crescent Capital BDC acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Crescent Capital BDC
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCrescent Capital BDC Investment Activity
Crescent Capital BDC invested in XXX companies to date.
Crescent Capital BDC made its latest investment on XXXXXXXX, XXXXX. Crescent Capital BDC invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Crescent Capital BDC
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Crescent Capital BDC
| When was Crescent Capital BDC founded? | Crescent Capital BDC was founded in 2015. |
| Where is Crescent Capital BDC headquartered? | Crescent Capital BDC is headquartered in United States. |
| How many employees does Crescent Capital BDC have? | As of today, Crescent Capital BDC has over 230 employees. |
| Who is the CEO of Crescent Capital BDC? | Crescent Capital BDC's CEO is Jason Breaux. |
| Is Crescent Capital BDC publicly listed? | Yes, Crescent Capital BDC is a public company listed on Nasdaq. |
| What is the stock symbol of Crescent Capital BDC? | Crescent Capital BDC trades under CCAP ticker. |
| When did Crescent Capital BDC go public? | Crescent Capital BDC went public in 2020. |
| Who are competitors of Crescent Capital BDC? | Crescent Capital BDC main competitors are abrdn Life Sciences, Testa Residencial, Qualitas, Djerriwarrh Investments. |
| What is the current market cap of Crescent Capital BDC? | Crescent Capital BDC's current market cap is $496M. |
| What is the current revenue of Crescent Capital BDC? | Crescent Capital BDC's last 12 months revenue is $164M. |
| What is the current revenue growth of Crescent Capital BDC? | Crescent Capital BDC revenue growth (NTM/LTM) is (6%). |
| What is the current EV/Revenue multiple of Crescent Capital BDC? | Current revenue multiple of Crescent Capital BDC is 8.3x. |
| Is Crescent Capital BDC profitable? | Yes, Crescent Capital BDC is net-income-positive (as of the last 12 months). |
| What is the current net income of Crescent Capital BDC? | Crescent Capital BDC's last 12 months net income is $41M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.